People’s Daily Health Client Chen Linhui
On July 27, the 5th China International Import Expo ushered in the 100-day countdown to the opening. According to incomplete statistics from the People’s Daily Health Client, more than 30 pharmaceutical companies including Johnson & Johnson, Pfizer, AstraZeneca, Merck, Takeda, Bayer, Novartis, Abbott and Eli Lilly have entered the first three batches of exhibitors at the fifth CIIE. The medical device and medicine and health care exhibition area of the list of merchants. In July, a number of pharmaceutical companies began to “spoiler” exhibition arrangements one after another.
Johnson & Johnson: will exhibit for five consecutive years and has exhibited thousands of innovative products
“Since the first CIIE, Johnson & Johnson has never This year, we will go to the Expo again.” Song Weiqun, Senior Vice President of Johnson & Johnson Global and Chairman of China, told China News Network that in the past four CIIEs, Johnson & Johnson has exhibited a total of 1,000 innovative products, including many Chinese premiers. Show, Asian premiere, and even the world’s premiere products. At present, Johnson & Johnson has built and put into operation innovative supply chain production bases in many places in China. In June 2022, Guangzhou Beixiu Biotechnology Co., Ltd., a wholly-owned subsidiary of Johnson & Johnson Medical Technology in China, announced that it would invest 150 million yuan to officially launch the “upgrade and expansion project”. After it is put into operation in 2025, the overall production capacity is expected to increase by 140%.
Johnson & Johnson’s booth in the medical equipment and healthcare exhibition area of the 4th CIIE. Photo of China International Import Expo Bureau
Pfizer: By 2025, it plans to introduce 25 new products into China
Pfizer will go to “import and export” Bozhiyue”, plans to introduce 25 new products to China in 2025. At the 5th CIIE, Pfizer will exhibit the theme of “Forging ahead for a new Pfizer, science wins the future”. Since January this year, Pfizer has brought 6 new products (including new indications and new dosage forms) to Chinese patients. Among them, PAXLOVID™, an oral drug for COVID-19 that has attracted much attention, was urgently approved with conditions in February this year, and the first batch of PAXLOVID ™ has arrived at China Customs in March. By 2025, Pfizer plans to introduce 25 new products (including new indications and new dosage forms) to China.
AstraZeneca: In the next 5 years, more than 60 new products will be approved in China
“Comprehensive display of breakthrough innovative drugs in multiple therapeutic areas and mechanism to demonstrate the scientific research strength of multinational pharmaceutical companies in China.” AstraZeneca, which has participated in the CIIE for four consecutive years, has already determined the exhibition orientation of the fifth CIIE. At present, AstraZeneca has more than 150 R&D projects under development in China, nearly 90% of which are being developed simultaneously with the world. It is expected that 60 to 65 new drugs and new indications will be approved in China in the next five years. AstraZeneca Global Executive Vice President Wang Lei told Chinanews.com, “In the future, as a localized multinational company rooted in China and going global, AstraZeneca will continue to play a bridge role, continue to increase investment in China, and promote regional economic and dual The development of circular economy will help China achieve high-quality development.”
Abbott: 550 square meters booth will display diversified innovation achievements
Abbott has participated in the exhibition for three consecutive years , this year will re-appear with innovative life and health solutions. It is understood that Abbott has successively displayed dozens of cutting-edge life technology and innovative products that were first shown in Asia and China through the Expo, and many of them have been successfully applied in China. Chen Ying, global vice president of Abbott Core Diagnostics and general manager of China, introduced: “Abbott will take the theme of ‘life technology empowers a healthy future’, and will display a comprehensive range of diagnostics, medical equipment, nutrition, and nutrition on a newly upgraded 550-square-meter booth. It focuses on the diversified innovation achievements in core business areas such as pharmaceuticals and pharmaceuticals, and focuses on more personalized and precise life-cycle health solutions.”